| __timestamp | MannKind Corporation | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 19586000 |
| Thursday, January 1, 2015 | 29674000 | 29135000 |
| Friday, January 1, 2016 | 14917000 | 42791000 |
| Sunday, January 1, 2017 | 14118000 | 49577000 |
| Monday, January 1, 2018 | 8737000 | 89209000 |
| Tuesday, January 1, 2019 | 6900000 | 69099000 |
| Wednesday, January 1, 2020 | 6248000 | 75961000 |
| Friday, January 1, 2021 | 12312000 | 90467000 |
| Saturday, January 1, 2022 | 19721000 | 74552000 |
| Sunday, January 1, 2023 | 31283000 | 91593000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, innovation is the key to staying ahead. This analysis compares the R&D spending of Supernus Pharmaceuticals, Inc. and MannKind Corporation from 2014 to 2023. Over this period, Supernus Pharmaceuticals consistently increased its R&D investment, peaking at approximately $91.6 million in 2023, a remarkable 368% increase from 2014. In contrast, MannKind Corporation's R&D spending saw a significant decline, dropping from a high of $100 million in 2014 to just over $31 million in 2023, a 69% decrease. This trend highlights Supernus Pharmaceuticals' commitment to innovation, while MannKind Corporation appears to have shifted its strategic focus. As the pharmaceutical landscape continues to change, these investment patterns may influence each company's future growth and market position.
Research and Development Investment: Pfizer Inc. vs Supernus Pharmaceuticals, Inc.
Bristol-Myers Squibb Company vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for BeiGene, Ltd. and Supernus Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Verona Pharma plc and Supernus Pharmaceuticals, Inc.
Ultragenyx Pharmaceutical Inc. or Supernus Pharmaceuticals, Inc.: Who Invests More in Innovation?
CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Catalyst Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
R&D Insights: How ImmunityBio, Inc. and MannKind Corporation Allocate Funds
R&D Spending Showdown: Protagonist Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Agios Pharmaceuticals, Inc. vs MannKind Corporation